A Former Navigator’s Perspective
The needs for navigation services were as varied as the individuals in need. More often than
not, the person who recognizes the need is a family member, friend or neighbour and only
sometimes the person in need of services or a healthcare provider.
Many calls were requests to sort out what type of service to [...]
The past decade has been transformed by new technologies that allow consumers to actively engage and interact in new and meaningful ways, including managing their finances, arranging travel, even communicating with friends and family using social networking! Yet, the same transformation towards actively engaging consumers in health care has not happened. While Canada’s health care [...]
Traditional Reimbursement Decision-Making Misses the Big Picture
By Geoff Sprang
Canadians are missing out on the health and wider societal benefits of new healthcare technologies because of our country’s overly simplistic drug evaluation process.
In adopting a narrow health system perspective and in focussing its assessment of value exclusively on a single parameter known as the cost per quality adjusted life year ($/QALY), the current Health Technology Assessment (HTA) process used in Canada fails to account for other variables that can greatly affect patient outcomes and add to the overall societal value of a medication…
When deciding on reimbursement criteria for pharmaceutical products, it’s understandable that makers must take a hard look at cost-effectiveness. After all, health expenditures, which are on the rise, must be managed within our public system.
Yet the emphasis on cost-benefit analyses, the lens through which we view public coverage, often leaves gaps in appropriate care options [...]
I read with great interest the paper by Geoff Sprang entitled :”Traditional reimbursement decision-making misses the big picture”. The drawbacks and flaws of $/QUALY, so dear to Canadian Health Technology Assessment, are too numerous and too well recognized to deserve further listing. This does not mean it should be totally abandoned since, at the very [...]
Healthcare reimbursement decision-making at the level of prescription drugs is complex and is based on a number of decision-making criterion like cost per quality-adjusted life year ($/QALY). Like a staged or hurdle process, the first and foremost consideration for prescription medication decisions is safety followed by efficacy and effectiveness. Cost-effectiveness analysis is a component of [...]
This site is supported and hosted by Amgen Canada
© 2012 All Rights Reserved.
Theme by sixty4media
